Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19186656 | 0.83 | NPC1 (0.60) | GAAMAOBRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18404750 | 0.82 | RAB9A (0.51) | RAB9AMAPTSMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL4829113 | 0.76 | MAPT (0.55) | MAOBMAPTNPC1 | |
| SCHEMBL14846356 | 0.74 | SMN1; SMN2 (0.46) | GAAMAOBRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL21384500 | 0.72 | RAB9A (0.46) | MAOBRAB9AMAPTMAOAL3MBTL1 | |
| SCHEMBL4831448 | 0.71 | GFER (0.52) | MAOBRAB9AMAPTSMN1; SMN2MAOA | |
| SCHEMBL655930 | 0.71 | MAPT (0.46) | GAAMAOBRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2095552 | 0.67 | — | — | |
| SCHEMBL655468 | 0.67 | RAB9A (0.80) | GAARAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL655929 | 0.67 | MAPT (0.84) | GAAMAOBRAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| EP-2583965-B1 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-8937055-B2 | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | UJIKAWA OSAMU (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2583965-A1 | HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | GAA 194/4885MAOB 3357/4885RAB9A 1957/4885 |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GAA 4645/4885MAOB 881/4885RAB9A 4059/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GAA 4645/4885MAOB 881/4885RAB9A 4059/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | GAA 194/4885MAOB 3357/4885RAB9A 1957/4885 |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | GAA 1190/4885MAOB 3932/4885RAB9A 2276/4885 |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | GAA 1190/4885MAOB 3932/4885RAB9A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.